Investigation of an Optimum Dosing Method of Levofloxacin 500 mg in Patients receiving Hemodialysis

Investigation of an Optimum Dosing Method of Levofloxacin 500 mg in Patients receiving Hemodialysis - Investigation of an Optimum Dosing Method of Levofloxacin 500 mg in Patients receiving Hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004077

Enrollment

Registered

2010-08-20

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacterial infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients receiving chronic dialysis during the study period, having infection, and selected LVFX treatment; 2)Patients competent to issue informed consent and having the intention to participe in the study (consent by a proxy consenter is also acceptable).

Exclusion criteria

Exclusion criteria: Patients hypersensitive to quinolones. Pregnant women or women of child bearing potential. Children under 18 years old. Patients with liver cirrhosis. Blood albumin level is 3g/dl or less. Patients receiving preparations containing iron, magnesium or aluminum with some particular methods; Patients whose weight is less than 40 kg; Patients with infection which is already known that the pathogen is unresponsive to LVFX, and the bacterial strain is clinically evidently ineffective; Other patients judged by the investigator or the sub-investigator as inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
Blood level of levofloxacin (Comparison of time course of residual blood level with non-dialysis patients as previously reported)	—

Countries

Japan

Outcome results